The investigator’s belief that the subject is medically unfit to receive pembrolizumab and or unsuitable for any other reason
The investigator’s belief that the subject is medically unfit to receive nivolumab, and/or ipilimumab or unsuitable for any other reason
Patients must be medically or surgically inoperable as determined by a physician OR unwilling to undergo surgical resection
Patients must be evaluated by a thoracic surgeon, pulmonologist or medical oncologist and deemed medically or surgically unacceptable for resection.
Medically unfit to undergo cystectomy or electively choosing to forego cystectomy
Be medically stable
Must be deemed medically fit for SBRT by the treating physician
Medically fit and willing to undergo resection of disease
Medically fit to undergo cystectomy
Patient desires and is medically fit to undergo prostatectomy
Deemed medically inoperable per urology evaluation
Must be considered medically fit for operation as determined by multidisciplinary evaluation
Patients must be considered unresectable or medically-inoperable
Patients must be medically fit enough to undergo surgery as determined by the surgical oncology team
SUITABLE DONOR – Medically cleared to donate
Patient is medically fit to receive cisplatin
Encephalopathy not adequately controlled medically
Patient has at least one medically fit family member expected to be HLA mismatched at 1-9/10 more commonly and preferred: 4-6/10 loci (e.g. parent, sibling, niece/nephew, etc. but adult children preferred)
Participant must be evaluated by surgical oncologist and felt to have potentially resectable tumor and be medically fit for proposed surgery
DONOR: Meets institutional selection criteria and medically fit to donate
Medically fit to undergo radical surgery as per treating surgeon's discretion
Medically fit, as defined by treatment-related mortality (TRM) score ?13.1 calculated with simplified model
Subjects must be medically fit to undergo surgery determined by the principal investigator (PI)
In the opinion of the investigator, patient must be medically fit to undergo surgical procedure
Medically unfit for anesthesia
Patients must have unresectable disease, be medically inoperable, or unwilling to undergo surgical management
Medically eligible to receive MEC
Medically eligible to receive \7+3\ cytarabine/idarubicin
Medically operable
Clinical status of either subject or tumor such that administration of 21 day neoadjuvant IRX-2 Regimen 1 or 2 before surgery would be medically inappropriate
Medically fit to and willing to donate
Deemed medically fit for stereotactic body radiation therapy by the treating physician
Patients must be medically fit enough to undergo surgery as determined by the treating medical and surgical oncology team
Willingness to use medically acceptable contraception
Patients must have resectable adenocarcinoma of the esophagus or GE-junction and are medically fit to undergo surgery; patients must have no evidence of distant metastasis based on imaging studies
Patients must have a Zubrod performance status of 0, 1, or 2 and in the registering physician’s opinion be medically suitable to undergo cystectomy
DONOR: Deemed medically unable to undergo bone marrow harvesting
Patients must be considered unresectable or medically inoperable; patients who decline surgery are also eligible
Patients are unwilling, or who are determined to be medically unfit for or resistant to standard intensive induction chemotherapy; patients who are medically unfit will be determined by the treating primary hematologist and the principal investigator (including but not limited to evaluation of co-morbidities, and response and complications to previous AML treatment strategy)
The investigator's belief that the participant is medically unfit to receive eribulin mesylate and pembrolizumab or unsuitable for any other reason.
Surgically or medically castrated, with testosterone levels of < 50 nanograms/deciliter.
Must be deemed medically fit for SBRT to the abdomen or thorax by the treating physician
The participant’s NSCLC must be considered medically inoperable for a standard lobectomy and mediastinal lymph node dissection/sampling procedure; the participant may have underlying physiological medical problems that would prohibit a surgery due to a low probability of tolerating general anesthesia, the operation, the postoperative recovery period, or the removal of adjacent functioning lung; these types of patients with severe underlying health problems are generally deemed “medically inoperable;\ standard justification for deeming a patient medically inoperable based on pulmonary function for surgical resection of NSCLC may include baseline forced expiratory volume in one second (FEV1) < 40% predicted, postoperative FEV1 < 30% predicted, severely reduced diffusion capacity, baseline hypoxemia and/or hypercapnia, severe pulmonary hypertension, severe cerebral, cardiac, or peripheral vascular disease; if the participant has medically operable disease but declines surgery after consulting with a thoracic surgeon, he/she will be considered eligible
DONOR: Medically fit to and willing to donate
Eligible patients should be deemed as likely to be medically fit to undergo surgical cytoreduction after 3 cycles of neoadjuvant chemotherapy by a surgical gynecologic oncologist
Patient must be considered medically inoperable as determined by the principal investigator
No medically documented preexisting auditory damage.
Any other medical condition for which treatment with ipilimumab or nivolumab would be medically contraindicated
Medically unable to undergo desensitization
Is medically, psychiatrically, or otherwise unable to participate (as determined by a physician or study principal investigator [PI])
Patient is considered medically unstable
Subjects who are not medically well enough to receive study therapy as determined by the investigator
Has been told by a doctor to have a heart condition and recommended only medically supervised activity
DONOR: medically fit to and willing to donate
Presence or recent history of other concurrent cancers, with the following exceptions: \r\n* Participants with completely treated basal or squamous skin cancers can be included in the study if their physicians deem that they are medically stable\r\n* Participants with completely treated in situ carcinoma of the breast or cervix may be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable\r\n* Participants with pre-cancerous lesions in the colon can be included in the study if they have not had chemotherapy within the past month and their physicians deem that they are medically stable
Have been using a Wii Fit
Women who are already participating in a formal or medically prescribed weight management program
Patients with ovarian cancer not medically fit for diagnostic laparoscopy prior to initiation of therapy
Patients who are medically fit for surgery defined as the following
Completed medically indicated physical therapy
NRT is medically contraindicated (e.g., recent heart attack within the last 2 weeks or, unstable/worsening angina)
Medically ineligible as a result of screening questions
Medically eligible to receive varenicline
Medically at risk in the judgment of the study physician
Healthy, medically well girls and boys
Medically stable as judged by patient’s physician
Patients who are medically unstable, terminally ill, or whose clinical course is unpredictable
Patients who are medically unstable, terminally ill, or whose clinical course is unpredictable
Medically stable as judged by patient’s physician
SUB-STUDY I: Patients considered as candidates for and medically fit to undergo prostatectomy
Medically stable as judged by patient’s physician.
PATIENT: Be medically stable
Patients considered as candidates for and medically fit to undergo radiation and ADT
Be medically stable.
Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.
Be medically stable
Patients who are medically unstable
Medically unstable
Be medically stable
Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
Be medically stable
Is medically or otherwise unable to participate (as determined by a physician or study principal investigator [PI])
